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Background: The existence of unilateral adrenal hyperplasia (AH) has been considered a rare cause of primary
hyperaldosteronism (PA).
Methods: In a prospective study we screened for PA in a non-selected (NSP) and selected hypertensive population
(SP), to define the cause of PA. We included 353 consecutive patients with hypertension; age 20 to 88 years, 165
women and 188 men, from a university-based Hypertension and Nephrology Outpatient clinics (123 SP) and two
primary care centres, (230 NSP) from the same catch-up area. Serum aldosterone and plasma renin activity (PRA)
were measured and the ARR calculated. Verifying diagnostic procedure was performed in patients with both
elevated aldosterone and ARR. Patients diagnosed with PA were invited for adrenal venous sampling (AVS) and
offered laparoscopic adrenalectomy when AVS found the disease to be unilateral.
Results: After screening, 46 patients, 13% of the whole population (22.8% SP and 7.8% NSP) had aldosterone and
ARR above the locally defined cut-off limits (0.43 nmol/l and 1.28 respectively). After diagnostic verification, 20
patients (6%) had PA, (14.5% SP and 1.4% NSP). Imaging diagnostic procedures with CT-scans and scintigraphy
were inconclusive. AVS, performed in 15 patients verified bilateral disease in 4 and unilateral in 10 patients. One AVS
failed. After laparoscopic adrenalectomy, 4 patients were found to have adenoma and 5 unilateral AH. One patient
denied operation.
Conclusion: The prevalence of PA was in agreement with previous studies. The study finds unilateral PA common
and unilateral AH as half of those cases. As may be suspected PA is found in much higher frequency in specialised
hypertensive units compared to primary care centers. AVS was mandatory in diagnosis of unilateral PA.
Keywords: Endocrine hypertension, Hyperaldosteronism, Aldosterone, Renin, Hypertension, Resistant hypertension,
Adrenal hyperplasiaBackground
Patients with primary hyperaldosteronism (PA) have
been found to have increased rate of cardiovascular
events compared to patients with primary HT [1]. PA is
now considered the most common form of secondary
HT. Studies from the last decade, using serum aldoster-
one/ renin ratio (ARR) for screening, have reported the* Correspondence: helga.sigurjonsdottir@medic.gu.se
1Department of Medicine, Centrum of Endocrinology and Metabolism,
Sahlgrenska University Hospital, University of Gothenburg, Gothenburg,
Sweden
Full list of author information is available at the end of the article
© 2012 Sigurjonsdottir et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumprevalence of PA to be higher than previously thought i.e.
from 4.6% to 22% in hypertensive populations [2,3],
depending on whether it is a non-selected patient group
(NSP) from primary care centres [2,4] versus selected
patient group (SP) from specialised HT clinics [2-15], study
design (prospective studies [2-7,9,11,13-15] versus retro-
spective [8,12,13]) and ethnicity of the studied population
[2,3,6,12].
Detecting PA secures specified, target treatment and
possible cure of the HT. Unilateral PA due to aldoster-
one producing adenoma (APA) or unilateral adrenal
hyperplasia (AH) can be a curable cause of HT. APA hasCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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AH has been considered a rare form of PA [16,17].The
biochemical cure rate of APA has been shown to in-
crease to up to 100% with the use of adrenal vein
sampling (AVS). AVS also minimizes the risk of adre-
nalectomy of a non-producing adrenal incidentaloma
[18-20].
It is not clear which patients should be screened for
PA [7,21,22] and there is no consensus on the cut-off
limits for ARR as they are method dependent and influ-
enced by environment and salt intake (salt-enriched or
salt deprived). The proposed advantages of using ARR as
a screening method is that this ratio is less influenced by
anti-hypertensive medical treatment and the physio-
logical variations of circulating levels of aldosterone and
renin [21]. Using the ARR together with s-aldosterone as
a screening tool has also been suggested to have higher
specificity than using only ARR [13]. Using cut-off
values above the 95th percentile of both s-aldosterone
and ARR in a normal population only 4.3% of screened
hypertensive patients had false positive results for PA
[7].
The aim of our study was screening for PA using lo-
cally produced cut-off limits of ARR and s-aldosterone,
verify the PA with confirmatory testing and defining
the aetiology by the use of computerised tomography,
AVS and post-operative histopathology (PAD) when PA
was found to be unilateral and surgically treated
[22,23,25].
Methods
Subjects and methods used to find cut off limits for
definition of PA
In order to define diagnostic limits for serum aldosterone
levels and ARR we included 39 patients with well defined
PA from the Sahlgrenska University Hospital and 36
healthy controls, all being Caucasian. A logistic regression
model and a ROC curve were used to define the sensitivity
and specificity of using s-aldosterone concentration and
ARR as a diagnostic marker for PA. A subgroup analysis
was performed using 16 patients (of the 39 with PA) who
had histologically proven aldosterone producing adenoma
(APA) post-operatively.
Subjects and methods used for screening for PA
Screening for PA was performed in a SP (n = 230) at
the Hypertension and Nephrology outpatient clinics at
Sahlgrenska University Hospital, Gothenburg and in a
NSP (n = 123) at two nearby primary care centres,
Mölnlycke and Nödinge. Ninety percent of patients
asked for participation, accepted, all being Caucasians,
resulting in a total population of 353 patients (230 SP
and 123 NSP). Inclusion criteria was HT defined as
systolic and diastolic blood pressure (SBP and DBPrespectively) above 140 mmHg and 90 mmHg respect-
ively, for at least 3 months, measured on at least 3 dif-
ferent occasions, before antihypertensive treatment was
initiated. Patients were included consecutively, having
both treated and newly diagnosed HT. In the morning,
after 10 minutes rest, blood pressure (BP) was mea-
sured twice with an accuracy of 2 mmHg using a mer-
cury sphygmomanometer, with the patient in a sitting
position. Blood samples for s-aldosterone and plasma
renin activity (PRA) were then collected and ARR cal-
culated. Urinary excretion of aldosterone and sodium
was then measured from a 12 hour over-night urinary
collection.
Subjects and methods to verify PA
Patients found to have elevated ARR and s-aldosterone
(group with suspected PA=SPA) were studied further
in order to verify PA. At a follow-up visit, sampling of
s-aldosterone and PRA was repeated after a 10-minute
rest in a sitting position and the ARR calculated. The
anti-hypertensive treatment was then changed in order
to eliminate medications affecting the RAAS. If needed,
patients received treatment with α-receptor inhibitor
and/or potassium supplementation and Ca2+- antago-
nists. Four to six weeks later (six weeks when the pa-
tient had been treated with spironolactone), patients
were studied again before and after a three days oral
salt-loading test (10 g of NaCl daily in three doses)
[23]. Normokalaemia was secured during those three
days. An aldosterone urinary excretion rate of more
than 28 nmol/day in the presence of urinary sodium
excretion of more than 250 mmol/day on the last day
of the salt-load is considered diagnostic for PA [21].
Patients having verified PA were studied further with
CT of the adrenals, 131I-cholesterol-scintigraphy and ad-
renal vein sampling (AVS), in order to find the affected
adrenal/adrenals.
Methods for adrenal vein sampling (AVS) and unilateral
Laparoscopic Adrenalectomy (LA)
An infusion, constituting 3 ml of cosyntropin (0.25 mg/ml)
and 800 ml of 0.9% NaCl, was given (rate 100 ml/hour)
for 90 minutes before the catheterisation or a total of
93.75 μg/hour of cosyntropin. Blood samples for cor-
tisol and aldosterone were taken from the femoral
vein, inferior vena cava and right and left adrenal
veins (RAV and LAV). Samples from the RAV were
analysed directly in order to secure a successful AVS.
When the cortisol value from the RAV was at least 10
times higher than that from infra-renal IVC (inferior vena
cava), the catheterisation could be completed after reach-
ing the LAV (performed in the mean-time while the corti-
sol level from the RAV was being measured), otherwise,
re-catheterisation of the RAV was done before concluding
Sigurjonsdottir et al. BMC Endocrine Disorders 2012, 12:17 Page 3 of 8
http://www.biomedcentral.com/1472-6823/12/17the AVS. Results from the AVS were then used to calcu-
late the lateralisation ratio in order to quantify unilateral
or bilateral overproduction of aldosterone [24,26-28]. The
lateralisation ratio is found by calculating the ratio of
aldosterone and cortisol for ipsilateral adrenal
IR¼ Aldosteronedominant adrenal vein=Cortisoldominant adrenal veinð Þ=ð
Aldosteroneperipheral vein=Cortisolperipheral vein
 Þ , for the contra-
lateral adrenal CR ¼ Aldosteronenondominant adrenal vein=ðð
Cortisol nondominant adrenal veinÞ = Aldosterone peripheral vein=

Cortisolperipheral veinÞÞ and then the lateral ratio IR/CR. In
order to define unilateral disease; the IR should be >1.4,
the CR <1 and the LR >3. When the lateralization ratio
indicated a unilateral disease; the affected adrenal gland
was removed by LA.Histopathological definition of adrenal hyperplasia vs.
adenoma
The histopathological definition of AH and adenomas
was in line with former descriptions [29,30]. AH would
have histopathology corresponding to microscopic
hyperplasia possible with nodular cortical hyperplasia
and adenomas should have atrophied or otherwise nor-
mal cortex with a single adenoma.Analytical methods
The serum and urinary sodium and potassium were
measured using ion selected electrode (Hitachi 911,
Roche Diagnostics, GmbH, Mannheim, Germany).
Radioimmunoassay (RIA) was used to measure serum
and urinary aldosterone (Aldosteron MAIA, Adaltis
Italia S.p.A., Roma, Italy).
The PRA determination involves an initial incubation of
plasma to generate angiotensin I, followed by quantification
of angiotensin I by RIA. The PRA was measured by one
RIA (ABBOTT, Diagnostic Division, Kista-Stockholm,
Sweden), for the first 227 patients. Due to the fact that
Abbott discontinued marketing their RIA kit in the middle
of our study, the last 126 patients had their PRA analyzed
by another RIA method (DIA), Gammacoat R, DiasSorin
Inc., Stillwater, USA. The latter method uses a procedure
based on competitive binding principles of radioimmuno-
assay, where the antibody is immobilized onto the lower
wall of the Gammacoat tube of the RIA kit. Seventy-four
samples were run in parallel using both methods, and there
was a highly significant correlation between the two mea-
surements (r = 0.97, p <0.0001). The first 227 PRA values
were corrected for the subsequent method in order to
minimize the effect of changing methods. PRA had a
within-run coefficient of variation of 8.8% and the lower
detection limit was 0.15 ng/ml/h. Serum cortisol was mea-
sured by RIA (Orion Diagnostica, Orion Corporation
Orion Diagnostica. Espoo, Finland).Ethics
Each participant received oral and written information
of the study and signed an informed consent before
being included into the study. The study was conducted
according to the guidelines of the Helsinki Declaration
of Helsinki and approved by the Regional Ethics Review
Board at the University of Gothenburg.
Statistical methods
To assess the diagnostic cut-off value of s-aldosterone
and the ARR, the receiver operating characteristic
(ROC) analysis was carried out.
A logistic regression model was performed to study
the relation between the s-aldosterone level and risk of
disease. In the analysis we plotted the ROC curve of
s-aldosterone and of the ARR as a predictor for PA. From
the analysis above, we then determined the best ‘cut-off ’
for each measure of interest.
Wilcoxon test was used for within group comparison
and for between-group comparisons the Mann–Whitney
test was used for calculations. A p-value <0.05 was con-
sidered significant.
Results
The cut-off levels for s-aldosterone and ARR
In the analyses of the 39 patients with PA and 36
healthy controls, the best cut-off for s-aldosterone was
0.44 nmol/L (90% sensitivity and 91% specificity) and
1.28 (82% sensitivity and 83% specificity) for the ARR.
In the analysis of the 16 patients with APA and the 36
healthy controls, the optimal cut-off for s-aldosterone
was 0.43 nmol/L (94% sensitivity and 91% specificity)
and 1.56 (94% sensitivity and 92% specificity) for ARR.
The cut-off point for s-aldosterone and ARR used in
the screening study was therefore decided to be
0.43 nmol/L for s-aldosterone and 1.28 for the ARR. In
order to minimize false positive PA both limits were
required.
The screening phase
Three hundred fifty-three consecutive patients, age 20 to
88 years, were included, (Table 1, Figure 1). Seventeen
patients were not on anti-hypertensive medication
(Table 1). Patients with resistant hypertension, treated
with more than 3 anti-hypertensive drugs were 9.4% of
the whole group, 21% SP and 3.5% NSP.
Forty-six patients (13%) had s-aldosterone and ARR
above 0.43 nmol/L and 1.28, respectively, 28 SP (7.9%)
and 18 NSP (5.1%). Thus 22.8% of the SP and 7.8% of
the NSP were above the defined cut-off limits for PA at
screening.
Comparing the 46 patients with suspected PA with the
rest of the screening population (RP, n = 307) mean DPB
was higher (p = 0.008, Table 1) and serum potassium
Table 1 Description of study population and anti-hypertensive treatment of the groups
Population
The rest of the screening population SPA-group
All (n = 307) SP (n = 94) NSP (n = 213) All (n =46) SP (n= 28) NSP (n = 18)
Female 164 47 117 18 11 7
Male 189 75 114 28 7 21
Age (years) 60.0 ± 11.1 56.0 ± 11.9 61.8 ± 10.3 59.7 ± 10.6 56.3 ± 10.8 65.1 ± 7.9
BMI (kg/m2) 28.7 ± 4.5 28.4 ± 5.2 28.8 ± 4.2 29.0 ± 4.2 28.6 ± 3.8 29.6 ± 4.7
Mean SBP (mmHg) 146.9 ± 21.0 149.9 ± 22.3 145.6 ± 20.4 152.0 ± 20.9 152.2 ± 20.9 152.7 ± 21.5
Mean DBP(mmHg 86.8 ± 10.6 87.5 ± 10.5 86.4 ± 10.7 91.0 ± 9.0 91.0 ± 8.1 90.9 ± 10.5
Duration of HT (years) 12.6 ± 9.8 13.1 ± 9.3 12.3 ± 10.1 12.9 ± 6.9 12.9 ± 5.6 12.8 ± 8.8
No of drugs* 1.8 ± 1.1 2.3 ± 1.3 1.6 ± 0.9 2.4 ± 1.1 2.6 ± 1.3 2.1 ± 0.8
No of drugs 0 to 3 279 75 204 39 21 18
No of drugs 4 to 5 26 18 8 7 7 0
β-blockers 165 60 105 34 22 12
ACE – & AII-inhibitors 154 60 94 24 16 8
diuretics 131 47 84 18 13 5
Spironolactone 0 0 0 2 2 0
Potassium supplements 14 8 6 3 3 0
Serum Potassium (mmol/l) 4.0 ± 0.4 3.9 ± 0.4 4.0 ± 0.4 3.7 ± 0.3 3.7 ± 0.5 3.7 ± 0.3
The rest of the screening population (n = 307 = 353-46, i.e. the whole screening population – the SPA group) and the group suspected with primary
hyperaldosteronism (the SPA group) due to the defined cut-off limits for serum aldosterone and serum aldosterone/renin ratio (ARR). SP = selected population.
NSP = non-selected population. No of medicine = total number of antihypertensive drugs at the time of screening, presented as the mean value ± standard
deviation. Respective antihypertensive drug is presented as total number of patients treated with it. β-blockers = β –receptor inhibitor. ACE = angiotensin
converting enzyme. AII = angiotensin II. *Information on drugs is missing for 2 patients not being in the SPA-group.
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Also the group with suspected PA had more often a his-
tory of low serum potassium levels (14 of 46 vs. 26 of
307, p <0.0001). No difference was, however, found in
body mass index (BMI), age, duration of HT or mean
SBP (Table 1). Patients with suspected PA were more
frequently treated with β-receptor blockers (74% vs.
54%, p <0.05), Ca2 +−channel blockers (54% vs. 35%46 patients 
with
suspected 
PA
1
w
28 patients studied 
with verifying tests 
for PA
22 SP
6 NSP
18 pat excluded
28 SP
18 NSP
230 NSP
123 SP
353 HT 
patients
screened
Figure 1 The study populations. From the whole screening population (
hyperaldosteronism (n = 46) and the subsequent study group studied for th
after endoscopic adrenal surgery. NSP = non-selective population, SP = selec
PA= Primary aldosteronism, PAD= histopathological diagnosis.p = 0.03) and peripheral vasodilators and α-receptor inhi-
bitors, (59% vs. 36%, p = 0.01).
Verification of PA
Of the 46 patients with suspected PA eighteen patients
did not participate due to another concomitant illness,
they had moved or refused further investigation. The 28
patients studied further are described in Table 2.4 Adenoma
5 NAH
5 patients 
studied
ith AVS
9 patients 
with PAD-
verified PA
Unilateral 
vs bilateral 
PA
13 SP
2 NSP
1 failed
8 pat normal
3 pat excluded
Unilateral 
PA
10 SP
2 AH
1 resist op
Bilateral PA
2 NSP
2 SP
n= 353), to the group found to have suspected primary
e diagnose of PA all the way to PAD (post-operative histopathology)
tive population, pat = patients, NAH=nodular adrenal hyperplasia,
Table 2 Patients included in the study
Study number Study popul-ation ARR Serum aldosterone (nmol/L) CT 131I-chol-scint AVS Diagnose PAD
1 14 NSP 1.30 0.69 - - - AH
2 1042 NSP 2.50 0.54 + (L) - - AH
3 1052 NSP 3.10 0.46 / / / Normal
4 1065 NSP 4.30 0.64 + (R) - Excluded
5 1092 NSP 1.50 0.75 / / / Normal
6 1105 NSP 2.00 0.62 / / / Normal
7 2002 SP 2.10 0.60 / / / Normal
8 2006 SP 3.80 0.49 - (x2) + (B) + (L) APA (L) NAH
9 2007 SP 4.30 0.64 + (R) - + (R) APA (R) NAH
10 2010 SP 2.90 0.43 -(?L) - + (L?) APA/AH Adenoma
11 2014 SP 4.50 0.68 - - (?R) + (R) APA (R) NAH
12 2022 SP 6.80 1.29 - - - AH
13 2036 SP 2.90 0.43 / / / Normal
14 2037 SP 4.50 0.95 / / / Normal
15 2042 SP 1.70 0.44 - - + (L) APA (L) NAH
16 2049 SP 9.30 1.39 + - Excluded
17 2060 SP 3.30 0.89 + (R) - + (R) APA (R)
18 2069 SP 1.64 0.56 / / / Normal
19 2070 SP 2.40 0.88 + (L) - - AH
20 2074 SP 4.95 0.65 - / / AH
21 2082 SP 3.80 0.50 - / / AH
22 2083 SP 2.10 1.10 + (R) + (R) + (R) APA (R) Adenoma
23 2084 SP 3.90 0.86 - + (L) + (L) APA (L) Adenoma
24 2086 SP 1.40 0.60 + (L) - + (L) APA (L) NAH
25 2099 SP 7.20 1.69 + (L) - + (L) APA (L) Adenoma
26 2100 SP 3.80 0.50 / / / Normal
27 3005 SP 2.10 0.62 - Excluded
28 3006 SP 3.50 0.94 - - failed
Population defines if the patient was screened in a non-selective (NSP) or a selective (SP) hypertensive population. Values for serum aldosterone and the ratio of
s-aldosterone/plasma renin activity (ARR) at inclusion and results of the adrenal CT (CT), 131I-norcholesterol-scintigraphy (131I-chol-scint) and adrenal vein sampling
(AVS) are given. For the CT, 131I-chol-scint and AVS the following symbols are used +, - , / and failed, for positive, bilateral overproduction of aldosterone, not
executed and failed investigation respectively. The letters (L), (R) and (B) indicate left, right and bilateral respectively. In the diagnose column, Normal, AH and APA
are used for normal ie no hyperaldosteronism, adrenal hyperplasia and aldosterone producing adenoma respectively. In the PAD column, NAH is used for cortical
nodular hyperplasia and adenoma for cortical adenoma.
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the mean value of s-aldosterone, PRA and ARR did not
differ from those collected at the time of screening (data
not shown). During drug adjustment two patients devel-
oped heart failure and were excluded from further evalu-
ation and the third patient denied further evaluation at
this point. Eight patients were found to have a normal
salt-loading test (2.3% of the whole screening population
and 29% of the 28 patients studied further) and were not
studied further. Two of the patients found to be normal
were treated with potassium supplements.
Of the 20 patients (5.7%) found to have PA after verifi-
cation, there were 3 women and 17 men. Thus, 17 SP
(14.5% of the SP) and 3 NSP (1.4% of the NSP) hadverified PA, excluding the 18 drop outs from the original
group.
Two of the 20 patients found to have PA, had results
comparable to AH and a negative CT-adrenals (CT)
(and then assumed to have bilateral PA at that time)
and were not studied further (pat no 2074 and 2082
Table 2).
Results of objective research, AVS, LA and
histopathological findings
Nine patients had positive and 9 patients had negative
findings on CT-adrenals (CT). Two patients had a visible
adenoma in the left adrenal on CT although AVS
demonstrated a bilateral disease. One patient had only a
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of aldosterone by AVS and after LA, PAD confirmed
APA. One patient had a negative CT finding, unilateral
overproduction of aldosterone by AVS and PAD after
LA confirmed APA. Three patients had positive findings
on 131I-cholesterol-scintigraphy and 14 negative, six of
those 14 patients were found to have unilateral overpro-
duction of aldosterone by AVS. One patient with bilat-
eral positive finding on scintigraphy had unilateral
overproduction of aldosterone after AVS and PAD con-
firmed unilateral AH (See Table 2).
Fifteen patients were studied with AVS and 3 patients
were excluded (two denied to be studied further and one
was excluded due to age). Four patients had lateralisa-
tion ratio after AVS indicating bilateral AH and received
medical treatment. Ten patients were found to have uni-
lateral PA and 9 of them went further to LA, one patient
denied operation.AVS failed to reach the RAV in one
patient.
After LA, five of the 9 patients were diagnosed with
AH and 4 with adenoma, verified by PAD (Table 2).
Histopathological findings found that all adenomas
demonstrated otherwise normal or atrophied adrenal
cortical structure except one that also has nodular hyper-
plasia. All specimens diagnosed with hyperplasia had a
microscopic character of nodular cortical hyperplasia.
Results on BP and serum potassium after LA
Three months after LA, five of the nine patients, had
fewer anti-hypertensive drugs, BP was somewhat lower
in three other patients with the same anti-hypertensive
treatment as before the LA and one patient had 5 anti-
hypertensive drugs after LA compared to three before
(Table 3).Table 3 Results on blood pressure, anti-hypertensive drugs a
Laparoscopic Adrenalectomy
Study
number
At baseline Laparo-scopic
Adrenal-ectomy
3
BP
(mmHg)
No
anti-HT
drugs
K+ subst.
yes/no
PAD B
(mm
2006 162/100 4 no NAH 154
2007 170/95 2 no NAH 140
2010 185/107 3 yes Adenoma 154
2014 164/97 4 no NAH 165
2042 167/94 3 no NAH 130
2083 150/90 2 yes Adenoma 135
2084 141/78 1 no Adenoma 120
2086 158/89 4 yes NAH 140
2099 138/94 3 no Adenoma
Results are presented for data at baseline, three months after Laparoscopic Adrenale
number of Anti-hypertensive drugs (No anti-HT drugs), potassium substitution (K + sOne year after LA, two patients are treated with fewer
anti-hypertensive drugs, one of them being cured from
HT and not needing anti-hypertensive drugs at all. Two
other patients were treated with the same amount of
anti-hypertensive drugs after LA as before. Further in-
formation on anti-hypertensive drugs used one year after
LA was missing for 5 patients (Table 3).
All the nine patients had serum potassium levels in
the upper normal reference values at 3 and 12 months
after LA. Two of the three patients needing potassium
substitution before LA were cured by LA, in one of
them information on potassium substitution one year
after LA was missing but 3 months after LA the need
for potassium substitution was cured (Table 3).
Discussion
In summary, after prospective screening of a hyperten-
sive population, unilateral AH was found to be as com-
mon as APA in patients with PA and unilateral disease.
Earlier publications suggest that unilateral AH is an
uncommon cause of unilateral PA with the highest
reported prevalence being 1 of 3 operated cases [31].
Our study indicates that the prevalence of unilateral AH
is higher. In a recent review on the subject unilateral PA
is presented as 2% of PA, bilateral hyperplasia as 60%
and unilateral adenoma as 35% [32]. Our results are in
huge discrepancy with this. By using AVS and
lateralization index a unilateral dominant disease can be
defined although it does not preclude the possibility of
the contra lateral gland being entirely free from hyper-
plasia [33]. As adrenalectomy with the use of a laparo-
scopic technique has become much easier and to be
cost-beneficial over long-term medical therapy, it is of
increasing interest to find patients with unilateral PAnd potassium supplementation in patients treated with
months after Laparoscopic
Adrenalectomy
1 year after Laparoscopic
Adrenalectomy
P
Hg)
No
anti-HT
drugs
K+ subst.
yes/no
BP
(mmHg)
No
anti-HT
drugs
K+ suppl.
yes/no
/90 2 no 128/80 3 no
/100 2 no 120/82 2 no
/94 3 yes 215/110 3 yes
/85 3 no - - -
/88 5 no - - -
/75 1 no 150/70 - no
/70 1 no - - -
/86 3 no - - -
- 2 - 140/80 0 no
ctomy and one year after Laparoscopic Adrenalectomy. Blood pressure (BP),
ubst.), post-operative histopathology (PAD), Nodular adrenal hyperplasia (NAH).
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APA or unilateral AH has been found to normalise hypo-
kalaemia in all cases, improve HT in 60-90% of the cases,
reverse left ventricular geometry and alter myocardial
texture [35] and not the least increase quality of life [36].
Our results support that patients with verified PA
should be further studied with AVS in order to deter-
mine whether a unilateral or a bilateral disease is at
hand, as previously suggested [15,37]. It has been postu-
lated that surgically correctable PA in the HT population
is less than 1.5%, in this study we found it to be 2.6%
and as high as 59% of those with confirmed PA (10 of 17
patients) [38]. The results on BP, anti-hypertensive treat-
ment and need for potassium substitution before,
3 months and one year after surgery lend further sup-
port to this conclusion (Table 3).
We found positive screening results in a high proportion
of patients with HT in both the specialised (22.8%) and
non-specialist (7.8%) hypertensive units, which is, in line
with recent studies [2-15].Our study therefore confirms
previous conclusions that awareness of PA should be high
among patients with HT in both SP and NSP [33,39].
The importance of screening is signified by the fact that
patients with PA have more HT related organic complica-
tions compared to those with primary HT [1,40-47].
Which patients should be screened? The clinical features
of patients with PA are not specific as they can have nor-
mal potassium concentrations and be without treatment
resistant HT [21,25]. Even so, our study indicates that
patients with a resistant increase in DBP and in the lower
normal interval of serum potassium should be included in
the population investigated for PA.
The caveats of using CT in detection of APA has to do
with the smallness of the adenomas that can easily be
missed as well as the fact that many adrenal adenoma
are non-functioning [48]. We found imaging results to
be confounding in up to half of the cases and the use of
scintigraphy was not helpful in the etiological work-up
of patients with PA. This emphasizes the importance of
using AVS in detection of unilateral vs. bilateral PA.
AVS needs to be executed by an experienced radiologist,
due to the anatomy of the right adrenal vein, that often
causes a failing procedure. This indicates that AVS
should only be performed in specialised centers.
The limitations of our study are the size of the study
population, the numbers of drop outs restraining the
final confirmation test. Moreover, bilateral AH cannot
be totally excluded as only the adrenal gland with the
dominant production of aldosterone was surgically
removed in those cases classified an unilateral AH. The
strength of our study is, however, the locally defined cut-
off limits for ARR and s-aldosterone used for screening.
The study was also prospective in consecutive patients
from both NSP and SP from the same catch up area.Conclusion
We conclude that in this prospective study the overall
prevalence of PA is higher among patients with HT
cared for in a specialised unit. The use of AVS was
found to be mandatory in the detection of unilateral PA
as imaging results and scintigraphy, were unreliable in
that perspective. In this study, unilateral AH was as
common as unilateral APA.
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